Pfizer Current Ratio 2012-2026 | PFE
Current and historical current ratio for Pfizer (PFE) from 2012 to 2026. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Pfizer current ratio for the three months ending March 31, 2026 was 0.00.
| Pfizer Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2026-03-31 | $0.00B | 0.00 | |
| 2025-12-31 | $0.00B | 0.00 | |
| 2025-09-30 | $46.92B | $36.60B | 1.28 |
| 2025-06-30 | $43.70B | $37.73B | 1.16 |
| 2025-03-31 | $45.86B | $36.45B | 1.26 |
| 2024-12-31 | $50.36B | $43.00B | 1.17 |
| 2024-09-30 | $43.22B | $43.21B | 1.00 |
| 2024-06-30 | $37.83B | $43.82B | 0.86 |
| 2024-03-31 | $42.42B | $40.50B | 1.05 |
| 2023-12-31 | $43.33B | $47.79B | 0.91 |
| 2023-09-30 | $74.01B | $31.14B | 2.38 |
| 2023-06-30 | $73.35B | $34.65B | 2.12 |
| 2023-03-31 | $50.08B | $36.56B | 1.37 |
| 2022-12-31 | $51.26B | $42.14B | 1.22 |
| 2022-09-30 | $70.40B | $44.31B | 1.59 |
| 2022-06-30 | $67.47B | $47.41B | 1.42 |
| 2022-03-31 | $54.42B | $39.27B | 1.39 |
| 2021-12-31 | $59.69B | $42.67B | 1.40 |
| 2021-09-30 | $57.90B | $41.80B | 1.39 |
| 2021-06-30 | $48.81B | $35.66B | 1.37 |
| 2021-03-31 | $39.53B | $26.65B | 1.48 |
| 2020-12-31 | $35.07B | $25.92B | 1.35 |
| 2020-09-30 | $47.74B | $34.15B | 1.40 |
| 2020-06-30 | $46.42B | $32.72B | 1.42 |
| 2020-03-31 | $34.74B | $33.89B | 1.03 |
| 2019-12-31 | $32.80B | $37.30B | 0.88 |
| 2019-09-30 | $33.46B | $36.97B | 0.91 |
| 2019-06-30 | $47.07B | $32.03B | 1.47 |
| 2019-03-31 | $45.29B | $29.42B | 1.54 |
| 2018-12-31 | $49.93B | $31.86B | 1.57 |
| 2018-09-30 | $41.58B | $29.01B | 1.43 |
| 2018-06-30 | $37.30B | $32.16B | 1.16 |
| 2018-03-31 | $34.84B | $27.37B | 1.27 |
| 2017-12-31 | $41.14B | $30.43B | 1.35 |
| 2017-09-30 | $40.29B | $28.22B | 1.43 |
| 2017-06-30 | $36.39B | $27.18B | 1.34 |
| 2017-03-31 | $35.88B | $24.86B | 1.44 |
| 2016-12-31 | $38.95B | $31.12B | 1.25 |
| 2016-09-30 | $38.50B | $34.76B | 1.11 |
| 2016-06-30 | $43.85B | $32.10B | 1.37 |
| 2016-03-31 | $41.30B | $28.74B | 1.44 |
| 2015-12-31 | $43.80B | $29.40B | 1.49 |
| 2015-09-30 | $45.00B | $27.85B | 1.62 |
| 2015-06-30 | $51.72B | $24.14B | 2.14 |
| 2015-03-31 | $49.44B | $20.22B | 2.45 |
| 2014-12-31 | $55.60B | $21.59B | 2.58 |
| 2014-09-30 | $56.99B | $19.92B | 2.86 |
| 2014-06-30 | $58.29B | $21.94B | 2.66 |
| 2014-03-31 | $57.79B | $24.79B | 2.33 |
| 2013-12-31 | $56.24B | $23.37B | 2.41 |
| 2013-09-30 | $59.50B | $20.37B | 2.92 |
| 2013-06-30 | $61.44B | $23.45B | 2.62 |
| 2013-03-31 | $64.76B | $27.54B | 2.35 |
| 2012-12-31 | $64.83B | $29.19B | 2.22 |
| 2012-09-30 | $57.13B | $29.13B | 1.96 |
| 2012-06-30 | $58.77B | $30.80B | 1.91 |
| 2012-03-31 | $54.86B | $27.09B | 2.03 |
| 2011-12-31 | $60.82B | $28.91B | 2.10 |
| 2011-09-30 | $62.73B | $27.86B | 2.25 |
| 2011-06-30 | $60.48B | $30.47B | 1.99 |
| 2011-03-31 | $58.24B | $29.17B | 2.00 |
| 2010-12-31 | $61.01B | $28.64B | 2.13 |
| 2010-09-30 | $54.09B | $24.17B | 2.24 |
| 2010-06-30 | $51.10B | $24.68B | 2.07 |
| 2010-03-31 | $49.92B | $25.92B | 1.93 |
| 2009-12-31 | $61.67B | $37.23B | 1.66 |
| 2009-09-30 | $73.78B | $23.99B | 3.08 |
| 2009-06-30 | $71.55B | $26.11B | 2.74 |
| 2009-03-31 | $54.25B | $23.34B | 2.32 |
| 2008-12-31 | $43.08B | $27.01B | 1.60 |
| 2008-09-30 | $48.23B | $21.50B | 2.24 |
| 2008-06-30 | $48.65B | $23.19B | 2.10 |
| 2008-03-31 | $51.01B | $21.68B | 2.35 |
| 2007-12-31 | $46.85B | $21.84B | 2.15 |
| 2007-09-30 | $41.84B | $14.33B | 2.92 |
| 2007-06-30 | $41.62B | $15.14B | 2.75 |
| 2007-03-31 | $42.34B | $13.30B | 3.18 |
| 2006-12-31 | $47.66B | $22.10B | 2.16 |
| 2006-09-30 | $38.72B | $17.69B | 2.19 |
| 2006-06-30 | $40.99B | $20.06B | 2.04 |
| 2006-03-31 | $37.42B | $19.67B | 1.90 |
| 2005-12-31 | $46.84B | $28.40B | 1.65 |
| 2005-09-30 | $32.77B | $20.40B | 1.61 |
| 2005-06-30 | $33.57B | $22.57B | 1.49 |
| 2005-03-31 | $42.35B | $28.95B | 1.46 |
| 2004-12-31 | $39.09B | $26.46B | 1.48 |
| 2004-09-30 | $39.06B | $25.24B | 1.55 |
| 2004-06-30 | $36.69B | $25.16B | 1.46 |
| 2004-03-31 | $35.39B | $24.64B | 1.44 |
| 2003-12-31 | $30.68B | $23.91B | 1.28 |
| 2003-09-30 | $33.07B | $21.66B | 1.53 |
| 2003-06-30 | $34.74B | $22.16B | 1.57 |
| 2003-03-31 | $31.10B | $18.75B | 1.66 |
| 2002-12-31 | $24.78B | $18.56B | 1.34 |
| 2002-09-30 | $23.67B | $18.40B | 1.29 |
| 2002-06-30 | $22.39B | $16.32B | 1.37 |
| 2002-03-31 | $20.97B | $14.73B | 1.42 |
| 2001-12-31 | $19.21B | $13.73B | 1.40 |
| 2001-09-30 | $20.00B | $13.04B | 1.53 |
| 2001-06-30 | $19.60B | $11.98B | 1.64 |
| 2001-03-31 | $18.70B | $10.87B | 1.72 |
| 2000-12-31 | $17.19B | $11.98B | 1.44 |
| 2000-09-30 | $17.17B | $12.34B | 1.39 |
| 2000-06-30 | $15.82B | $12.22B | 1.29 |
| 2000-03-31 | $10.43B | $7.48B | 1.40 |
| 1999-12-31 | $11.19B | $9.19B | 1.22 |
| 1999-09-30 | $11.48B | $9.09B | 1.26 |
| 1999-06-30 | $11.15B | $8.81B | 1.27 |
| 1999-03-31 | $10.75B | $7.75B | 1.39 |
| 1998-12-31 | $9.93B | $7.19B | 1.38 |
| 1998-09-30 | $9.87B | $7.26B | 1.36 |
| 1998-06-30 | $8.26B | $6.14B | 1.35 |
| 1998-03-31 | $7.41B | $5.68B | 1.30 |
| 1997-12-31 | $6.82B | $5.31B | 1.29 |
| 1997-09-30 | $7.24B | $5.78B | 1.25 |
| 1997-06-30 | $7.34B | $6.42B | 1.14 |
| 1997-03-31 | $6.93B | $5.78B | 1.20 |
| 1996-12-31 | $6.47B | $5.64B | 1.15 |
| 1996-09-30 | $6.81B | $6.20B | 1.10 |
| 1996-06-30 | $6.49B | $5.85B | 1.11 |
| 1996-03-31 | $6.41B | $5.48B | 1.17 |
| 1995-12-31 | $6.15B | $5.19B | 1.19 |
| 1995-09-30 | $6.14B | $5.80B | 1.06 |
| 1995-06-30 | $5.98B | $6.10B | 0.98 |
| 1995-03-31 | $5.83B | $5.78B | 1.01 |
| 1994-12-31 | $5.79B | $4.83B | 1.20 |
| 1994-09-30 | $5.43B | $4.14B | 1.31 |
| 1994-06-30 | $5.17B | $4.29B | 1.21 |
| 1994-03-31 | $4.94B | $3.75B | 1.32 |
| 1993-12-31 | $4.73B | $3.44B | 1.37 |
| 1993-09-30 | $5.70B | $4.15B | 1.37 |
| 1993-06-30 | $5.75B | $4.10B | 1.40 |
| 1993-03-31 | $5.44B | $3.62B | 1.50 |
| 1992-12-31 | $5.39B | $3.22B | 1.67 |
| 1992-09-30 | $5.64B | $3.22B | 1.75 |
| 1992-06-30 | $5.00B | $3.16B | 1.58 |
| 1992-03-31 | $4.71B | $3.05B | 1.55 |
| 1991-12-31 | $4.81B | $3.42B | 1.41 |
| 1991-09-30 | $4.36B | $3.23B | 1.35 |
| 1991-06-30 | $4.36B | $3.26B | 1.34 |
| 1991-03-31 | $4.26B | $2.83B | 1.51 |
| 1990-12-31 | $4.44B | $3.12B | 1.42 |
| 1990-09-30 | $3.88B | $2.68B | 1.45 |
| 1990-06-30 | $3.96B | $2.58B | 1.54 |
| 1990-03-31 | $4.05B | $2.35B | 1.72 |
| 1989-12-31 | $4.51B | $2.91B | 1.55 |
| 1989-09-30 | $3.80B | $2.32B | 1.64 |
| 1989-06-30 | $3.77B | $2.43B | 1.55 |
| 1989-03-31 | $4.06B | $2.16B | 1.88 |
| 1988-12-31 | $4.10B | $2.34B | 1.75 |
| 1988-09-30 | $3.98B | $2.05B | 1.94 |
| 1988-06-30 | $4.08B | $2.05B | 1.99 |
| 1988-03-31 | $4.09B | $1.87B | 2.18 |
| 1987-12-31 | $4.10B | $1.96B | 2.10 |
| 1987-09-30 | $2.73B | $1.49B | 1.84 |
| 1987-06-30 | $2.68B | $1.49B | 1.81 |
| 1987-03-31 | $2.46B | $1.22B | 2.01 |
| 1986-12-31 | $2.96B | $1.23B | 2.40 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |